Search
Now showing items 11-20 of 26
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
(OXFORD UNIV PRESS, 2022-03-04)
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic ...
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
(NATURE PORTFOLIO, 2022-07-20)
The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated ...
A Delphi consensus statement for digital surgery.
(NATURE PORTFOLIO, 2022-07-19)
The use of digital technology is increasing rapidly across surgical specialities, yet there is no consensus for the term 'digital surgery'. This is critical as digital health technologies present technical, governance, and ...
Micro-CT acquisition and image processing to track and characterize pulmonary nodules in mice.
(NATURE PORTFOLIO, 2022-12-09)
X-ray computed tomography is a reliable technique for the detection and longitudinal monitoring of pulmonary nodules. In preclinical stages of diagnostic or therapeutic development, the miniaturized versions of the clinical ...
Physical Characteristics of SurgiMend Meshed Biological ADM in Immediate Prepectoral Implant Breast Reconstruction.
(LIPPINCOTT WILLIAMS & WILKINS, 2022-06-01)
With increasing acceptance of prepectoral implant breast reconstruction, there has been a requirement for biological acellular dermal matrices with conformational properties, high tensile strength, and rapid integration. ...
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
(NATURE PORTFOLIO, 2022-11-29)
The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD ...
What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unit.
(BMJ PUBLISHING GROUP, 2022-11-28)
INTRODUCTION: Novel therapies such as small protein molecule inhibitors and immunotherapies are tested in early phase trials before moving to later phase trials and ultimately standard practice. A key aim of these clinical ...
Systematic study of tissue factor expression in solid tumors.
(WILEY, 2022-08-13)
BACKGROUND: Elevated tissue factor (TF) expression, although restricted in normal tissue, has been reported in multiple solid cancers, and expression has been associated with poor prognosis. This manuscript compares TF ...
Targeting an Initiator Allergen Provides Durable and Expansive Protection against House Dust Mite Allergy.
(AMER CHEMICAL SOC, 2022-09-09)
Whereas treatment of allergic diseases such as asthma relies largely on the targeting of dysregulated effector pathways, the conceptually attractive alternative of preventing them by a pharmaceutical, at-source intervention ...